Click for best price
Myasthenia Gravis Disease Drugs Market Size, Share 2022
Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and relaxation of muscles which are crucial for carrying out daily activities, resulting in muscle weakness. It mostly affects the muscles that control the eyes and eyelids, facial expressions, chewing, and speaking.
This report contains market size and forecasts of Myasthenia Gravis Disease Drugs in Global, including the following market information:
Global Myasthenia Gravis Disease Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Myasthenia Gravis Disease Drugs market was valued at 1467.3 million in 2021 and is projected to reach US$ 2400 million by 2028, at a CAGR of 7.3% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Acetylcholinesterase Inhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Myasthenia Gravis Disease Drugs include GlaxoSmithKline, Novartis, Teva Pharmaceutical, Roche, Bristol-Myers Squibb, Apotex, Cipla, Biogen and AbbVie, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Myasthenia Gravis Disease Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Myasthenia Gravis Disease Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Myasthenia Gravis Disease Drugs Market Segment Percentages, by Type, 2021 (%)
Acetylcholinesterase Inhibitors
Immunosuppressant Drugs
Steroid
Others
Global Myasthenia Gravis Disease Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Myasthenia Gravis Disease Drugs Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Myasthenia Gravis Disease Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Myasthenia Gravis Disease Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Myasthenia Gravis Disease Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Myasthenia Gravis Disease Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
GlaxoSmithKline
Novartis
Teva Pharmaceutical
Roche
Bristol-Myers Squibb
Apotex
Cipla
Biogen
AbbVie
Bausch Health
Sun Pharmaceuticals
| Report Attributes |
Report Details |
| Report Title |
Myasthenia Gravis Disease Drugs Market - Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
60 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Myasthenia Gravis Disease Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Myasthenia Gravis Disease Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Myasthenia Gravis Disease Drugs Overall Market Size
2.1 Global Myasthenia Gravis Disease Drugs Market Size: 2021 VS 2028
2.2 Global Myasthenia Gravis Disease Drugs Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Myasthenia Gravis Disease Drugs Players in Global Market
3.2 Top Global Myasthenia Gravis Disease Drugs Companies Ranked by Revenue
3.3 Global Myasthenia Gravis Disease Drugs Revenue by Companies
3.4 Top 3 and Top 5 Myasthenia Gravis Disease Drugs Companies in Global Market, by Revenue in 2021
3.5 Global Companies Myasthenia Gravis Disease Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Myasthenia Gravis Disease Drugs Players in Global Market
3.6.1 List of Global Tier 1 Myasthenia Gravis Disease Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Myasthenia Gravis Disease Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Myasthenia Gravis Disease Drugs Market Size Markets, 2021 & 2028
4.1.2 Acetylcholinesterase Inhibitors
4.1.3 Immunosuppressant Drugs
4.1.4 Steroid
4.1.5 Others
4.2 By Type - Global Myasthenia Gravis Disease Drugs Revenue & Forecasts
4.2.1 By Type - Global Myasthenia Gravis Disease Drugs Revenue, 2017-2022
4.2.2 By Type - Global Myasthenia Gravis Disease Drugs Revenue, 2023-2028
4.2.3 By Type - Global Myasthenia Gravis Disease Drugs Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Myasthenia Gravis Disease Drugs Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Myasthenia Gravis Disease Drugs Revenue & Forecasts
5.2.1 By Application - Global Myasthenia Gravis Disease Drugs Revenue, 2017-2022
5.2.2 By Application - Global Myasthenia Gravis Disease Drugs Revenue, 2023-2028
5.2.3 By Application - Global Myasthenia Gravis Disease Drugs Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Myasthenia Gravis Disease Drugs Market Size, 2021 & 2028
6.2 By Region - Global Myasthenia Gravis Disease Drugs Revenue & Forecasts
6.2.1 By Region - Global Myasthenia Gravis Disease Drugs Revenue, 2017-2022
6.2.2 By Region - Global Myasthenia Gravis Disease Drugs Revenue, 2023-2028
6.2.3 By Region - Global Myasthenia Gravis Disease Drugs Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Myasthenia Gravis Disease Drugs Revenue, 2017-2028
6.3.2 US Myasthenia Gravis Disease Drugs Market Size, 2017-2028
6.3.3 Canada Myasthenia Gravis Disease Drugs Market Size, 2017-2028
6.3.4 Mexico Myasthenia Gravis Disease Drugs Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Myasthenia Gravis Disease Drugs Revenue, 2017-2028
6.4.2 Germany Myasthenia Gravis Disease Drugs Market Size, 2017-2028
6.4.3 France Myasthenia Gravis Disease Drugs Market Size, 2017-2028
6.4.4 U.K. Myasthenia Gravis Disease Drugs Market Size, 2017-2028
6.4.5 Italy Myasthenia Gravis Disease Drugs Market Size, 2017-2028
6.4.6 Russia Myasthenia Gravis Disease Drugs Market Size, 2017-2028
6.4.7 Nordic Countries Myasthenia Gravis Disease Drugs Market Size, 2017-2028
6.4.8 Benelux Myasthenia Gravis Disease Drugs Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Myasthenia Gravis Disease Drugs Revenue, 2017-2028
6.5.2 China Myasthenia Gravis Disease Drugs Market Size, 2017-2028
6.5.3 Japan Myasthenia Gravis Disease Drugs Market Size, 2017-2028
6.5.4 South Korea Myasthenia Gravis Disease Drugs Market Size, 2017-2028
6.5.5 Southeast Asia Myasthenia Gravis Disease Drugs Market Size, 2017-2028
6.5.6 India Myasthenia Gravis Disease Drugs Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Myasthenia Gravis Disease Drugs Revenue, 2017-2028
6.6.2 Brazil Myasthenia Gravis Disease Drugs Market Size, 2017-2028
6.6.3 Argentina Myasthenia Gravis Disease Drugs Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Myasthenia Gravis Disease Drugs Revenue, 2017-2028
6.7.2 Turkey Myasthenia Gravis Disease Drugs Market Size, 2017-2028
6.7.3 Israel Myasthenia Gravis Disease Drugs Market Size, 2017-2028
6.7.4 Saudi Arabia Myasthenia Gravis Disease Drugs Market Size, 2017-2028
6.7.5 UAE Myasthenia Gravis Disease Drugs Market Size, 2017-2028
7 Players Profiles
7.1 GlaxoSmithKline
7.1.1 GlaxoSmithKline Corporate Summary
7.1.2 GlaxoSmithKline Business Overview
7.1.3 GlaxoSmithKline Myasthenia Gravis Disease Drugs Major Product Offerings
7.1.4 GlaxoSmithKline Myasthenia Gravis Disease Drugs Revenue in Global Market (2017-2022)
7.1.5 GlaxoSmithKline Key News
7.2 Novartis
7.2.1 Novartis Corporate Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Myasthenia Gravis Disease Drugs Major Product Offerings
7.2.4 Novartis Myasthenia Gravis Disease Drugs Revenue in Global Market (2017-2022)
7.2.5 Novartis Key News
7.3 Teva Pharmaceutical
7.3.1 Teva Pharmaceutical Corporate Summary
7.3.2 Teva Pharmaceutical Business Overview
7.3.3 Teva Pharmaceutical Myasthenia Gravis Disease Drugs Major Product Offerings
7.3.4 Teva Pharmaceutical Myasthenia Gravis Disease Drugs Revenue in Global Market (2017-2022)
7.3.5 Teva Pharmaceutical Key News
7.4 Roche
7.4.1 Roche Corporate Summary
7.4.2 Roche Business Overview
7.4.3 Roche Myasthenia Gravis Disease Drugs Major Product Offerings
7.4.4 Roche Myasthenia Gravis Disease Drugs Revenue in Global Market (2017-2022)
7.4.5 Roche Key News
7.5 Bristol-Myers Squibb
7.5.1 Bristol-Myers Squibb Corporate Summary
7.5.2 Bristol-Myers Squibb Business Overview
7.5.3 Bristol-Myers Squibb Myasthenia Gravis Disease Drugs Major Product Offerings
7.5.4 Bristol-Myers Squibb Myasthenia Gravis Disease Drugs Revenue in Global Market (2017-2022)
7.5.5 Bristol-Myers Squibb Key News
7.6 Apotex
7.6.1 Apotex Corporate Summary
7.6.2 Apotex Business Overview
7.6.3 Apotex Myasthenia Gravis Disease Drugs Major Product Offerings
7.6.4 Apotex Myasthenia Gravis Disease Drugs Revenue in Global Market (2017-2022)
7.6.5 Apotex Key News
7.7 Cipla
7.7.1 Cipla Corporate Summary
7.7.2 Cipla Business Overview
7.7.3 Cipla Myasthenia Gravis Disease Drugs Major Product Offerings
7.7.4 Cipla Myasthenia Gravis Disease Drugs Revenue in Global Market (2017-2022)
7.7.5 Cipla Key News
7.8 Biogen
7.8.1 Biogen Corporate Summary
7.8.2 Biogen Business Overview
7.8.3 Biogen Myasthenia Gravis Disease Drugs Major Product Offerings
7.8.4 Biogen Myasthenia Gravis Disease Drugs Revenue in Global Market (2017-2022)
7.8.5 Biogen Key News
7.9 AbbVie
7.9.1 AbbVie Corporate Summary
7.9.2 AbbVie Business Overview
7.9.3 AbbVie Myasthenia Gravis Disease Drugs Major Product Offerings
7.9.4 AbbVie Myasthenia Gravis Disease Drugs Revenue in Global Market (2017-2022)
7.9.5 AbbVie Key News
7.10 Bausch Health
7.10.1 Bausch Health Corporate Summary
7.10.2 Bausch Health Business Overview
7.10.3 Bausch Health Myasthenia Gravis Disease Drugs Major Product Offerings
7.10.4 Bausch Health Myasthenia Gravis Disease Drugs Revenue in Global Market (2017-2022)
7.10.5 Bausch Health Key News
7.11 Sun Pharmaceuticals
7.11.1 Sun Pharmaceuticals Corporate Summary
7.11.2 Sun Pharmaceuticals Business Overview
7.11.3 Sun Pharmaceuticals Myasthenia Gravis Disease Drugs Major Product Offerings
7.11.4 Sun Pharmaceuticals Myasthenia Gravis Disease Drugs Revenue in Global Market (2017-2022)
7.11.5 Sun Pharmaceuticals Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Myasthenia Gravis Disease Drugs Market Opportunities & Trends in Global Market
Table 2. Myasthenia Gravis Disease Drugs Market Drivers in Global Market
Table 3. Myasthenia Gravis Disease Drugs Market Restraints in Global Market
Table 4. Key Players of Myasthenia Gravis Disease Drugs in Global Market
Table 5. Top Myasthenia Gravis Disease Drugs Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Myasthenia Gravis Disease Drugs Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Myasthenia Gravis Disease Drugs Revenue Share by Companies, 2017-2022
Table 8. Global Companies Myasthenia Gravis Disease Drugs Product Type
Table 9. List of Global Tier 1 Myasthenia Gravis Disease Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Myasthenia Gravis Disease Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Myasthenia Gravis Disease Drugs Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Myasthenia Gravis Disease Drugs Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Myasthenia Gravis Disease Drugs Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Myasthenia Gravis Disease Drugs Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Myasthenia Gravis Disease Drugs Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Myasthenia Gravis Disease Drugs Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2023-2028
Table 30. GlaxoSmithKline Corporate Summary
Table 31. GlaxoSmithKline Myasthenia Gravis Disease Drugs Product Offerings
Table 32. GlaxoSmithKline Myasthenia Gravis Disease Drugs Revenue (US$, Mn), (2017-2022)
Table 33. Novartis Corporate Summary
Table 34. Novartis Myasthenia Gravis Disease Drugs Product Offerings
Table 35. Novartis Myasthenia Gravis Disease Drugs Revenue (US$, Mn), (2017-2022)
Table 36. Teva Pharmaceutical Corporate Summary
Table 37. Teva Pharmaceutical Myasthenia Gravis Disease Drugs Product Offerings
Table 38. Teva Pharmaceutical Myasthenia Gravis Disease Drugs Revenue (US$, Mn), (2017-2022)
Table 39. Roche Corporate Summary
Table 40. Roche Myasthenia Gravis Disease Drugs Product Offerings
Table 41. Roche Myasthenia Gravis Disease Drugs Revenue (US$, Mn), (2017-2022)
Table 42. Bristol-Myers Squibb Corporate Summary
Table 43. Bristol-Myers Squibb Myasthenia Gravis Disease Drugs Product Offerings
Table 44. Bristol-Myers Squibb Myasthenia Gravis Disease Drugs Revenue (US$, Mn), (2017-2022)
Table 45. Apotex Corporate Summary
Table 46. Apotex Myasthenia Gravis Disease Drugs Product Offerings
Table 47. Apotex Myasthenia Gravis Disease Drugs Revenue (US$, Mn), (2017-2022)
Table 48. Cipla Corporate Summary
Table 49. Cipla Myasthenia Gravis Disease Drugs Product Offerings
Table 50. Cipla Myasthenia Gravis Disease Drugs Revenue (US$, Mn), (2017-2022)
Table 51. Biogen Corporate Summary
Table 52. Biogen Myasthenia Gravis Disease Drugs Product Offerings
Table 53. Biogen Myasthenia Gravis Disease Drugs Revenue (US$, Mn), (2017-2022)
Table 54. AbbVie Corporate Summary
Table 55. AbbVie Myasthenia Gravis Disease Drugs Product Offerings
Table 56. AbbVie Myasthenia Gravis Disease Drugs Revenue (US$, Mn), (2017-2022)
Table 57. Bausch Health Corporate Summary
Table 58. Bausch Health Myasthenia Gravis Disease Drugs Product Offerings
Table 59. Bausch Health Myasthenia Gravis Disease Drugs Revenue (US$, Mn), (2017-2022)
Table 60. Sun Pharmaceuticals Corporate Summary
Table 61. Sun Pharmaceuticals Myasthenia Gravis Disease Drugs Product Offerings
Table 62. Sun Pharmaceuticals Myasthenia Gravis Disease Drugs Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Myasthenia Gravis Disease Drugs Segment by Type in 2021
Figure 2. Myasthenia Gravis Disease Drugs Segment by Application in 2021
Figure 3. Global Myasthenia Gravis Disease Drugs Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Myasthenia Gravis Disease Drugs Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Myasthenia Gravis Disease Drugs Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Myasthenia Gravis Disease Drugs Revenue in 2021
Figure 8. By Type - Global Myasthenia Gravis Disease Drugs Revenue Market Share, 2017-2028
Figure 9. By Application - Global Myasthenia Gravis Disease Drugs Revenue Market Share, 2017-2028
Figure 10. By Region - Global Myasthenia Gravis Disease Drugs Revenue Market Share, 2017-2028
Figure 11. By Country - North America Myasthenia Gravis Disease Drugs Revenue Market Share, 2017-2028
Figure 12. US Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Myasthenia Gravis Disease Drugs Revenue Market Share, 2017-2028
Figure 16. Germany Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 17. France Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Myasthenia Gravis Disease Drugs Revenue Market Share, 2017-2028
Figure 24. China Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 28. India Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Myasthenia Gravis Disease Drugs Revenue Market Share, 2017-2028
Figure 30. Brazil Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Myasthenia Gravis Disease Drugs Revenue Market Share, 2017-2028
Figure 33. Turkey Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Myasthenia Gravis Disease Drugs Revenue, (US$, Mn), 2017-2028
Figure 37. GlaxoSmithKline Myasthenia Gravis Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Novartis Myasthenia Gravis Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Teva Pharmaceutical Myasthenia Gravis Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Roche Myasthenia Gravis Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Bristol-Myers Squibb Myasthenia Gravis Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Apotex Myasthenia Gravis Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Cipla Myasthenia Gravis Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Biogen Myasthenia Gravis Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. AbbVie Myasthenia Gravis Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Bausch Health Myasthenia Gravis Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Sun Pharmaceuticals Myasthenia Gravis Disease Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
